LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

LLY

751.49

+0.07%↑

JNJ

153.95

+1.34%↑

UNH

323.91

+3.75%↑

ABBV

184.94

-0.06%↓

NVO

68.4

+2.97%↑

Search

Arcutis Biotherapeutics Inc

Aperta

SettoreSettore sanitario

14.37 -0.07

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

14.11

Massimo

14.69

Metriche Chiave

By Trading Economics

Entrata

-14M

-25M

Vendite

-5.5M

66M

EPS

-0.2

Margine di Profitto

-38.059

Dipendenti

342

EBITDA

-20M

-25M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+35.65% upside

Dividendi

By Dow Jones

Utili prossimi

13 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-101M

1.7B

Apertura precedente

14.44

Chiusura precedente

14.37

Notizie sul Sentiment di mercato

By Acuity

23%

77%

54 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 mag 2025, 20:40 UTC

Acquisizioni, Fusioni, Takeovers

FedEx Names CEO, Chairman for Planned Freight Spinoff

20 mag 2025, 00:00 UTC

Notizie principali

America's Fiscal Situation Threatens the Good Mood on Wall Street -- WSJ

19 mag 2025, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About Moody's U.S. Downgrade Ease -- Market Talk

19 mag 2025, 23:43 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Technical Correction -- Market Talk

19 mag 2025, 23:22 UTC

Notizie principali

Crypto Billionaire Accused of Defrauding Creditors, Propelling Industry's 2022 Collapse -- WSJ

19 mag 2025, 22:33 UTC

Discorsi di Mercato

Uranium Buyers Could Accelerate Restocking -- Market Talk

19 mag 2025, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Yuexiu Property to Use Divestment Proceeds for Business Development Purposes

19 mag 2025, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Yuexiu Property to Sell Stake for CNY4.15B

19 mag 2025, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Yuexiu Property to Sell Stake to China Resources Land

19 mag 2025, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Yuexiu Property to Sell 65% Stake in Beijing Haizhen Real Estate

19 mag 2025, 22:02 UTC

Utili

Trip.com Group 1Q Rev $1.9B >TCOM

19 mag 2025, 22:02 UTC

Utili

Trip.com Group 1Q Adj EPS 82c >TCOM

19 mag 2025, 22:02 UTC

Utili

Trip.com Group 1Q EPS 84c >TCOM

19 mag 2025, 21:58 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

19 mag 2025, 21:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

19 mag 2025, 21:58 UTC

Discorsi di Mercato

Automakers to Raise Prices by End of June, Toyota COO Says -- Market Talk

19 mag 2025, 21:50 UTC

Notizie principali
Utili

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19 mag 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

19 mag 2025, 20:48 UTC

Notizie principali

Home Depot's Earnings Could Mirror a Sluggish Housing Market -- Barrons.com

19 mag 2025, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

FedEx: R. Brad Martin, Vice Chmn of the FedEx Corp. Bd of Directors, Agreed to Serve as Chmn of the Bd of FedEx Freight >FDX

19 mag 2025, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

FedEx: Both Appointments Will Be Effective Upon Completion of the Previously Announced Separation of FedEx Freight From FedEx Corp. >FDX

19 mag 2025, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

FedEx: Plans for the Spinoff, Which Is Expected to Occur by June 2026, Remain on Track >FDX

19 mag 2025, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

FedEx: Announces Leadership for Independent FedEx Freight Co Upon Separation

19 mag 2025, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

FedEx: John A. Smith, Oper Chief, U.S. and Canada, of Federal Express, Has Been Selected as Pres and CEO of FedEx Freight >FDX

19 mag 2025, 20:20 UTC

Notizie principali

Major U.S. Stock Indexes Finish Higher; Dollar Falls -- WSJ

19 mag 2025, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Steel Stock Rises on Report of Better Nippon Offer. Why Trump Could Say 'Yes.' -- Barrons.com

19 mag 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

19 mag 2025, 19:59 UTC

Notizie principali

JPMorgan CEO Dimon Still Intends to Step Down in Next Few Years. 'It's Up to the Board.' -- Barrons.com

19 mag 2025, 19:58 UTC

Discorsi di Mercato

Estonia Redirects Ships After Russia Detains Greek Tanker -- Market Talk

19 mag 2025, 19:52 UTC

Discorsi di Mercato

Imports Accelerate at Southern California Ports -- Market Talk

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

35.65% in crescita

Previsioni per 12 mesi

Media 19.14 USD  35.65%

Alto 21 USD

Basso 15 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

7

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

12.42 / 14.93Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

54 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.